title: Activation of kinin B1 receptor increases the release of metalloproteases-2 and -9 from both estrogen-sensitive and -insensitive breast cancer cells.
abstract: The kinin B(1) receptor (B(1)R) agonist Lys-des[Arg(9)]-bradykinin (LDBK) increases proliferation of estrogen-sensitive breast cancer cells by a process involving activation of the epidermal growth factor receptor (EGFR) and downstream signaling via the ERK1/2 mitogen-activated protein kinase pathway. Here, we investigated whether B(1)R stimulation induced release of the extracellular matrix metalloproteases MMP-2 and MMP-9 via ERK-dependent pathway in both estrogen-sensitive MCF-7 and -insensitive MDA-MB-231 breast cancer cells. Cells were stimulated with 1-100nM of the B(1)R agonist for variable time-points. Western blotting and gelatin zymography were used to evaluate the presence of MMP-2 and MMP-9 in the extracellular medium. Stimulation of B(1)R with as little as 1 nM LDBK induced the accumulation of these metalloproteases in the medium within 5-30min of stimulation. In parallel, immunocytochemistry revealed that metalloprotease levels in the breast cancer cells declined after stimulation. This effect was blocked either by pre-treating the cells with a B(1)R antagonist or by transfecting with B(1)R-specific siRNA. Activation of the ERK1/2 pathway and EGFR transactivation was required for release of metalloproteases because both the MEK1 inhibitor, PD98059, and AG1478, an inhibitor of the EGFR-tyrosine kinase activity, blocked this event. The importance of EGFR-dependent signaling was additionally confirmed since transfection of cells with the dominant negative EGFR mutant HERCD533 blocked the release of metalloproteases. Thus, activation of B(1)R is likely to enhance breast cancer cells invasiveness by releasing enzymes that degrade the extracellular matrix and thereby favor metastasis.
authors.affiliation: Instituto de Farmacologia y Morfofisiologia, Universidad Austral de Chile, Valdivia, Chile. pamelaehrenfeld74@gmail.com
authors.forename: Pamela
authors.initials: P
authors.lastname: Ehrenfeld
authors.forename: Ivan
authors.initials: I
authors.lastname: Conejeros
authors.forename: Maria F
authors.initials: MF
authors.lastname: Pavicic
authors.forename: Carola E
authors.initials: CE
authors.lastname: Matus
authors.forename: Carlos B
authors.initials: CB
authors.lastname: Gonzalez
authors.forename: Andrew F G
authors.initials: AF
authors.lastname: Quest
authors.forename: Kanti D
authors.initials: KD
authors.lastname: Bhoola
authors.forename: Maria T
authors.initials: MT
authors.lastname: Poblete
authors.forename: Rafael A
authors.initials: RA
authors.lastname: Burgos
authors.forename: Carlos D
authors.initials: CD
authors.lastname: Figueroa
mesh_terms: D001943:Breast Neoplasms / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D004967:Estrogens / Q000494:pharmacology*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000502:physiology; D005260:Female; D006801:Humans; D020935:MAP Kinase Signaling System; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D043783:Receptor, Bradykinin B1 / Q000819:agonists / Q000502:physiology*
chemical_list: D004967:Estrogens; D043783:Receptor, Bradykinin B1; D048049:Extracellular Signal-Regulated MAP Kinases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9